Participants will have type 2 diabetes and be using basal insulin (with or without oral medications and/or Glucagon-Like-Peptide-1 (GLP-1) analogue) and have an elevated Hemoglobin A1C of 8.0 – 11.5.
Continuous Glucose Monitoring in Type 2 Diabetes Basal Insulin Users
The Mobile Study
Study Length: 14 Months
Target Age/Sex: 30 or over, Male and Female
Participants will receive at no cost: study product, study materials and study-specific procedures